Company intelligence / Profile preview
Yousen Jianheng Biomedical
Shanghai, Chinayusen-logistics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Yousen Jianheng Biomedical has several programs in early clinical development, including small molecules and biologics targeting oncology and immunology indications. The most advanced program is in Phase 1/2 for multiple myeloma; other assets are in Phase 1 for arthritis, anaphylaxis, solid tumors, and neoplasms. Targets include TYK2, KRAS G12D mutation, and IL‑17A.
- Therapeutic areas
- ImmunologyRheumatologyOncology
- Modalities
- Small moleculeBiological productRecombinant proteinBispecific monoclonal antibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Yousen Jianheng Biomedical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Yousen Jianheng Biomedical.